Engineering a Multi Epitope Vaccine Against SARS-CoV-2 By Exploiting Its Non Structural and Structural Proteins

Abstract

<jats:title>Abstract</jats:title> <jats:p>SARS-CoV-2, the causative agent behind the ongoing pandemic exhibits an enhanced potential for infection when compared to its related family members- the SARS-CoV and MERS-CoV; which have caused similar disease outbreaks in the past. The severity of the global health burden, increasing mortality rate and the emergent economic crisis urgently demands the development of next- generation vaccines. Amongst such emergent next generation vaccines are the multi-epitope subunit vaccines, which hold promise in combating deadly pathogens. In this study we have exploited immunoinformatics applications to delineate a vaccine candidate possessing multiple B and T cells epitopes utilizing the SARS-CoV-2 non structural and structural proteins. The antigenicity potential, safety, structural stability and the production feasibility of the designed construct was evaluated computationally. Furthermore, due to the known crucial interactions of human TLR-3 immune receptor with SARS-CoV, the vaccine construct was examined for its binding efficiency using molecular docking and molecular dynamics simulation studies, which resulted in strong and stable interactions. Finally, the immune simulation studies suggested an effective immune response on vaccine administration. Overall, the immunoinformatics analysis advocates that the purposed vaccine candidate is safe and immunogenic and therefore can be pushed as a lead for <jats:italic>in vitro</jats:italic> and <jats:italic>in vivo </jats:italic>investigations.</jats:p>